Page last updated: 2024-10-21

n-methyl-3,4-methylenedioxyamphetamine and Anxiety

n-methyl-3,4-methylenedioxyamphetamine has been researched along with Anxiety in 71 studies

N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.

Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.

Research Excerpts

ExcerptRelevanceReference
"PubMed search from inception to March 11, 2022, using the terms anxiety, depression, psychedelics, psilocybin, lysergic acid, methylenedioxymethamphetamine, or ayahuasca."5.41Psychedelics for Patients With Cancer: A Comprehensive Literature Review. ( Dalo, J; Weisman, N; White, CM, 2023)
"Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test."5.32Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004)
" Our experiments were designed to examine the effects of a concomitant administration of 3,4-methylenedioxy-methamphetamine (MDMA) and mephedrone on depression- and anxiety-like behaviors and cognitive processes in Swiss mice."3.85Acute behavioral effects of co-administration of mephedrone and MDMA in mice. ( Biała, G; Budzynska, B; Frankowska, M; Kaszubska, K; Michalak, A, 2017)
" The possibility that some of these psychological problems are caused by ecstasy-induced neurotoxicity is supported by preclinical evidence of MDMA-induced neurotoxicity and behavioural deficits, evidence of depleted serotonin in heavy ecstasy users, and by dose-response relationships between the extent of exposure to ecstasy and the severity of cognitive impairments."2.41Ecstasy (MDMA): a review of its possible persistent psychological effects. ( Morgan, MJ, 2000)
"Despite its efficacy in PTSD and anxiety, MDMA did not reduce either the subjective or objective responses to stress in this controlled study."1.46MDMA does not alter responses to the Trier Social Stress Test in humans. ( Bershad, AK; de Wit, H; Miller, MA, 2017)
"The dependent variable was the number of reported ecstasy-related adverse effects."1.37Modelling the adverse effects associated with ecstasy use. ( Fisk, JE; Hadjiefthyvoulou, F; Montgomery, C; Murphy, PN, 2011)
" Locomotor activity and body weight were assessed during the dosing period and withdrawal-related anxiety was assessed 24 h after drug cessation."1.36Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. ( Arnold, JC; Hunt, GE; Long, LE; McGregor, IS; van Nieuwenhuijzen, PS, 2010)
" Regardless of dosing regimen, MDMA treatment produced path integration deficits as evidenced by an increase in latency to find the goal in the Cincinnati water maze."1.35(+/-)-3,4-Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks. ( Able, JA; Grace, CE; Gudelsky, GA; Herring, NR; Schaefer, TL; Skelton, MR; Vorhees, CV; Williams, MT, 2008)
" However, such dosing regimens do not adequately mimic the intermittent use patterns commonly seen in adolescent recreational ecstasy users."1.35Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence. ( Meyer, JS; Piper, BJ; Vancollie, VE, 2008)
"In recent work we have documented lasting adverse neurochemical and behavioural effects in rats given short-term 'binge' dosing with methylenedioxymethamphetamine (MDMA, Ecstasy), methamphetamine (METH) or their combination."1.34Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. ( Clemens, KJ; Cornish, JL; Hunt, GE; McGregor, IS, 2007)
"These results indicate that hyperthermia at the time of dosing with MDMA is not necessary to produce subsequent 5-HT depletion and anxiety in rats."1.32Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. ( Blokland, A; Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Morley, KC, 2003)
"Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test."1.32Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004)

Research

Studies (71)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (4.23)18.2507
2000's38 (53.52)29.6817
2010's28 (39.44)24.3611
2020's2 (2.82)2.80

Authors

AuthorsStudies
White, CM1
Weisman, N1
Dalo, J1
Wolfson, PE1
Andries, J1
Feduccia, AA2
Jerome, L2
Wang, JB1
Williams, E1
Carlin, SC1
Sola, E1
Hamilton, S1
Yazar-Klosinski, B2
Emerson, A2
Mithoefer, MC1
Doblin, R1
Bershad, AK1
Miller, MA1
de Wit, H1
Danforth, AL1
Grob, CS1
Struble, C1
Walker, N1
Scott, RM3
Hides, L3
Allen, JS3
Lubman, DI3
Wetherell, MA1
Montgomery, C2
Montagud-Romero, S1
Daza-Losada, M1
Vidal-Infer, A2
Maldonado, C3
Aguilar, MA3
Miñarro, J4
Rodríguez-Arias, M4
García-Pardo, MP1
Manzanedo, C1
Karimi, S1
Jahanshahi, M1
Golalipour, MJ1
Ramos, L1
Hicks, C1
Caminer, A1
Goodwin, J1
McGregor, IS11
Fulde, GW1
Forster, SL1
Johansson, EM1
García-Gutiérrez, MS1
Moscoso-Castro, M1
Manzanares, J1
Valverde, O4
Macúchová, E1
Ševčíková, M1
Hrebíčková, I1
Nohejlová, K1
Šlamberová, R1
Jones, L1
Reed, P1
Parrott, A1
Ponzoni, L1
Sala, M1
Braida, D1
Budzynska, B1
Michalak, A1
Frankowska, M1
Kaszubska, K1
Biała, G1
Hasler, F1
Studerus, E1
Lindner, K1
Ludewig, S1
Vollenweider, FX3
Skelton, MR2
Able, JA1
Grace, CE2
Herring, NR2
Schaefer, TL2
Gudelsky, GA1
Vorhees, CV2
Williams, MT2
Bedi, G1
Van Dam, NT1
Redman, J1
Meyer, JS2
Piper, BJ2
Vancollie, VE1
Adori, C2
Zelena, D1
Tímár, J1
Gyarmati, Z1
Domokos, A1
Sobor, M1
Fürst, Z1
Makara, G1
Bagdy, G3
Andó, RD2
Kirilly, E2
Molnár, E1
Kovács, GG1
Ferrington, L2
Kelly, PA2
Burke, R1
van Nieuwenhuijzen, PS1
Long, LE1
Hunt, GE8
Arnold, JC1
Fisk, JE1
Murphy, PN1
Hadjiefthyvoulou, F1
Ruiz-Medina, J3
Ledent, C1
Carretón, O1
Ferraz-de-Paula, V1
Stankevicius, D1
Ribeiro, A1
Pinheiro, ML1
Rodrigues-Costa, EC1
Florio, JC1
Lapachinske, SF1
Moreau, RL1
Palermo-Neto, J1
Guerri, C1
Ros-Simó, C1
Hare, BD1
D'Onfro, KC1
Hammack, SE1
Falls, WA1
Pinto-Xavier, A1
Kolyaduke, OV1
Hughes, RN1
Green, AR1
Parrott, AC1
Buchanan, T1
Scholey, AB1
Heffernan, T1
Ling, J1
Rodgers, J1
Navarro, JF2
Maldonado, E2
Clemens, KJ5
Van der Plasse, G1
Li, KM5
Chen, F1
Lawrence, AJ1
Gurtman, CG3
Morley, KC4
Blokland, A1
Cornish, JL4
Thompson, MR1
Verheyden, SL1
Maidment, R1
Curran, HV2
Van Nieuwenhuyzen, PS1
Sumnall, HR1
O'Shea, E1
Marsden, CA1
Cole, JC1
Ho, YJ1
Pawlak, CR1
Guo, L1
Schwarting, RK2
Check, E1
De Almeida, SP1
Silva, MT1
Mejias, S1
Rossignol, M1
Debatisse, D1
Streel, E1
Servais, L1
Guérit, JM1
Philippot, P1
Campanella, S1
Palenicek, T1
Votava, M1
Bubenikova, V1
Horacek, J1
Uys, JD1
Niesink, RJ1
Benko, A1
Hoshi, R1
Pratt, H1
Mehta, S1
Bond, AJ1
Lamers, CT1
Bechara, A1
Rizzo, M1
Ramaekers, JG1
Baumann, MH1
Wang, X1
Rothman, RB1
Walker, QD1
Williams, CN1
Jotwani, RP1
Waller, ST1
Francis, R1
Kuhn, CM1
Medina, KL1
Shear, PK1
Reid, LW1
Elifson, KW1
Sterk, CE1
Alati, R1
Kinner, SA1
Hayatbakhsh, MR1
Mamun, AA1
Najman, JM1
Williams, GM1
Ludwig, V1
Mihov, Y1
Cohen, RS1
Lin, HQ1
Burden, PM1
Christie, MJ1
Johnston, GA1
McCann, UD1
Eligulashvili, V1
Mertl, M1
Murphy, DL1
Ricaurte, GA1
Gamma, A1
Frei, E1
Lehmann, D1
Pascual-Marqui, RD1
Hell, D1
Liechti, ME1
Morgan, MJ1
Gallate, JE1
Mallet, PE1
Mechan, AO1
Moran, PM1
Elliott, M1
Young, AJ1
Joseph, MH1
Green, R1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness[NCT02427568]Phase 218 participants (Actual)Interventional2015-05-14Completed
Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417]Phase 2120 participants (Anticipated)Interventional2022-05-01Not yet recruiting
A Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults[NCT02008396]Phase 212 participants (Actual)Interventional2014-04-11Completed
Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI): A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder[NCT05138068]Phase 290 participants (Actual)Interventional2022-04-13Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Baseline STAI Trait Score

"The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: 3 months post-enrollment

Interventionscore on a scale (Mean)
Placebo With Therapy57.4
MDMA-assisted Therapy (125 mg)62.5

Change in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint

The Beck Depression Inventory-II (BDI-II) is a a 21-item self-reported measure of depression according to Diagnostic and Statistical Manual IV (DSM-IV) criteria. Each item is rated on a 4-point Likert scale ranging from 0 to 3. The total score is the sum of 21 items and range from 0 to 63. Score cutoffs indicate: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression. Higher scores indicate more severe depressive symptoms. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Interventionscore on a scale (Mean)
Placebo With Therapy-14.6
MDMA-assisted Therapy (125 mg)-20.9

Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint

The Global Assessment of Function (GAF) is a measure of a person's global social functioning made through clinical observation. The GAF consists of a single score, with scores ranging from 0 to 100, with 100 reflecting superior function and zero reflecting serious risk of causing harm to the self or others. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post 2nd experimental session)

Interventionscore on a scale (Mean)
Placebo With Therapy3.0
MDMA-assisted Therapy (125 mg)6.6

Change in MADRS Score From Baseline to Primary Endpoint

The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item, clinician administered questionnaire used to diagnose the severity of depressive episodes. Each item has a score of 0 to 6. Overall scores are summed and range from 0 to 60. Score cutoffs indicate: 0-6 normal/symptom absent, 7-19 mild depression, 20-34 moderate depression, > 34 severe depression. Higher scores indicate greater severe depression. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Interventionscore on a scale (Mean)
Placebo With Therapy-7.0
MDMA-assisted Therapy (125 mg)-10.5

Change in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint

The Pittsburgh Sleep Quality Index (PSQI) is a measure of self-reported sleep quality over a one month period. It consists of 19 items with possible responses ranging from zero to four on a five-point scale. The PSQI consists of seven sub-scales: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. These are all summed to produce a single global scale. Global scores can range from 0 to 21, with higher scores reflecting poorer sleep quality, and a score below 5 indicating good sleep quality. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Interventionscore on a scale (Mean)
Placebo With Therapy-0.2
MDMA-assisted Therapy (125 mg)-3.6

Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint

The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Interventionscore on a scale (Mean)
Placebo With Therapy-2.6
MDMA-assisted Therapy (125 mg)12.9

Change in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint

"The Self-Compassion Scale (SCS) is a 26-item self-reported questionnaire that assesses how respondents relate to themselves and treat themselves during difficult or painful experiences. Items are scored along a 5-point Likert-type scale ranging from 1 almost never to 5 almost always. The SCS has six component (subscale) scores: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Subscale scores are calculated by computing the mean of subscale item responses.~A total self-compassion score is calculated by the sum of the subscale scores and range from 24 to 120 with higher scores indicating greater self compassion. Higher scores have been found to correlate with positive mental health outcomes, as well as decreased depression and anxiety." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Interventionscore on a scale (Mean)
Placebo With Therapy-0.04
MDMA-assisted Therapy (125 mg)0.4

Change in STAI State Score From Baseline to Primary Endpoint

"The state subscale of the STAI (STAI-S) is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Like the trait subscale, participants respond to each item on the state subscale by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Interventionscore on a scale (Mean)
Placebo With Therapy-6.0
MDMA-assisted Therapy (125 mg)-22.1

Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint

"The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure was intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Interventionscore on a scale (Mean)
Placebo With Therapy-8.8
MDMA-assisted Therapy (125 mg)-23.5

Primary Endpoint STAI Trait Score

"The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: One month post-2nd experimental session

Interventionscore on a scale (Mean)
Placebo With Therapy48.6
MDMA-assisted Therapy (125 mg)38.9

Change in Death Attitudes Profile (DAP) From Baseline to Primary Endpoint

"The Death Attitudes Profile (DAP) is a 32-item self-reported questionnaire that assesses individual attitudes and beliefs about death and dying. Each item on the scale is rated along a 7-point Likert scale ranging from strongly disagree (score of 1) to strongly agree (score of 7), with higher scores indicating more positive attitudes toward death.~The DAP consists of 5 dimensions: fear of death (7 items summed with total scores ranging from 7 to 49), death avoidance (5 items summed with total scores ranging from 5 to 35), neutral acceptance (5 items summed with total scores ranging from 5 to 35), approach acceptance (10 items summed with total scores ranging from 10 to 70), and escape acceptance (5 items summed with total scores ranging from 5 to 35). For each dimension, a mean scale score can be computed by dividing the total scale score by the number of items forming each scale." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

,
Interventionscore on a scale (Mean)
Fear of deathDeath avoidanceNeutral acceptanceApproach acceptanceEscape acceptance
MDMA-assisted Therapy (125 mg)-0.100.10.30.4
Placebo With Therapy-0.6-1.10.2-0.10

Change in Functional Assessment of Chronic Illness Therapy Scale (FACIT) From Baseline to Primary Endpoint

The Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) is a 27-item self-report measure of quality of life issues specifically relevant to individuals with a chronic or life-threatening illness or condition. The core questionnaire consists of four subscales: Physical Well-being, Social/Family Well-being, Emotional Well-being, and Functional Well-being. Responses range from 0 (not at all) to 4 (very much), with higher scores indicating greater well-being. For each subscale, total scores were summed and range from 0 to 16. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

,
Interventionscore on a scale (Mean)
Physical well-beingSocial/ family well-beingEmotional well-beingFunctional well-beingAdditional concerns
MDMA-assisted Therapy (125 mg)1.40.81.64.84.5
Placebo With Therapy2.8-2.01.01.0-0.3

Change in Leibowitz Social Anxiety Scale (LSAS) Total Score From Baseline to 1-Month Post Experimental Session 2

The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: Baseline to 1-Month Post Experimental Session 2

Interventionscore on a scale (Mean)
Inactive Placebo With Psychotherapy-19.3
75 mg to 125 mg MDMA With Psychotherapy-44.1

Liebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 2

The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: 1-Month Post Experimental Session 2

Interventionscore on a scale (Mean)
Inactive Placebo With Psychotherapy64.0
75 mg to 125 mg MDMA With Psychotherapy46.4

Liebowitz Social Anxiety Scale (LSAS) Total Score at Baseline

The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: Baseline

Interventionscore on a scale (Mean)
Inactive Placebo With Psychotherapy83.3
75 mg to 125 mg MDMA With Psychotherapy91.8

Reviews

5 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Anxiety

ArticleYear
Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
    The Annals of pharmacotherapy, 2023, Volume: 57, Issue:9

    Topics: Antidepressive Agents; Anxiety; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Neopl

2023
The impact of amphetamine-type stimulants on emergency services.
    Current opinion in psychiatry, 2015, Volume: 28, Issue:4

    Topics: Acute Disease; Aggression; Amphetamine; Amphetamine-Related Disorders; Anxiety; Central Nervous Syst

2015
Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature.
    Drug and alcohol review, 2005, Volume: 24, Issue:4

    Topics: Anxiety; Body Temperature; Depression; Dopamine; Hallucinogens; Humans; Hydroxybutyrates; N-Methyl-3

2005
3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.
    Psychopharmacology, 2007, Volume: 189, Issue:4

    Topics: Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Brain; Dopamine; Dose-Response Relationship

2007
Ecstasy (MDMA): a review of its possible persistent psychological effects.
    Psychopharmacology, 2000, Volume: 152, Issue:3

    Topics: Affect; Aggression; Animals; Anxiety; Brain; Cognition Disorders; Humans; Memory; N-Methyl-3,4-methy

2000

Trials

8 trials available for n-methyl-3,4-methylenedioxyamphetamine and Anxiety

ArticleYear
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.
    Scientific reports, 2020, 11-24, Volume: 10, Issue:1

    Topics: Adult; Anxiety; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Humans;

2020
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.
    Scientific reports, 2020, 11-24, Volume: 10, Issue:1

    Topics: Adult; Anxiety; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Humans;

2020
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.
    Scientific reports, 2020, 11-24, Volume: 10, Issue:1

    Topics: Adult; Anxiety; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Humans;

2020
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.
    Scientific reports, 2020, 11-24, Volume: 10, Issue:1

    Topics: Adult; Anxiety; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Humans;

2020
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
    Psychopharmacology, 2018, Volume: 235, Issue:11

    Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum

2018
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
    Psychopharmacology, 2018, Volume: 235, Issue:11

    Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum

2018
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
    Psychopharmacology, 2018, Volume: 235, Issue:11

    Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum

2018
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
    Psychopharmacology, 2018, Volume: 235, Issue:11

    Topics: Adult; Anxiety; Autistic Disorder; Combined Modality Therapy; Double-Blind Method; Fear; Female; Hum

2018
Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA.
    Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:8

    Topics: Adult; Affect; Anxiety; Cognition; Double-Blind Method; Humans; Male; N-Methyl-3,4-methylenedioxyamp

2009
An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood - are there gender differences?
    Journal of psychopharmacology (Oxford, England), 2006, Volume: 20, Issue:2

    Topics: Adult; Affect; Aggression; Alcoholic Intoxication; Amphetamine-Related Disorders; Anxiety; Attention

2006
Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls.
    Journal of psychopharmacology (Oxford, England), 2006, Volume: 20, Issue:2

    Topics: Adult; Amphetamine-Related Disorders; Anxiety; Cognition Disorders; Decision Making; Depression; Dis

2006
Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.
    Psychopharmacology, 1999, Volume: 147, Issue:1

    Topics: Adult; Affect; Anxiety; Behavior; Female; Hallucinogens; Humans; Hydrocortisone; Male; N-Methyl-3,4-

1999
Mood state and brain electric activity in ecstasy users.
    Neuroreport, 2000, Jan-17, Volume: 11, Issue:1

    Topics: Adult; Affect; Anxiety; Electroencephalography; Female; Hallucinogens; Humans; Male; N-Methyl-3,4-me

2000
Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2000, Volume: 10, Issue:4

    Topics: Adult; Affect; Antipsychotic Agents; Anxiety; Blood Pressure; Body Temperature; Consciousness; Dopam

2000

Other Studies

58 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Anxiety

ArticleYear
MDMA does not alter responses to the Trier Social Stress Test in humans.
    Psychopharmacology, 2017, Volume: 234, Issue:14

    Topics: Anxiety; Blood Pressure; Central Nervous System Stimulants; Exercise Test; Hallucinogens; Heart Rate

2017
Coping style and ecstasy use motives as predictors of current mood symptoms in ecstasy users.
    Addictive behaviors, 2013, Volume: 38, Issue:10

    Topics: Adaptation, Psychological; Adolescent; Adult; Affective Symptoms; Anxiety; Australia; Child; Cross-S

2013
Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.
    Psychopharmacology, 2014, Volume: 231, Issue:7

    Topics: Anxiety; Case-Control Studies; Circadian Rhythm; Depression; Drug Users; Female; Humans; Hydrocortis

2014
The novelty-seeking phenotype modulates the long-lasting effects of intermittent ethanol administration during adolescence.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adolescent; Aging; Animals; Anxiety; Behavior, Animal; Cocaine; Ethanol; Exploratory Behavior; Human

2014
Effects of acute social stress on the conditioned place preference induced by MDMA in adolescent and adult mice.
    Behavioural pharmacology, 2014, Volume: 25, Issue:5-6

    Topics: Aging; Animals; Anxiety; Conditioning, Psychological; Corticosterone; Dominance-Subordination; Dose-

2014
The effect of MDMA-induced anxiety on neuronal apoptosis in adult male rats' hippocampus.
    Folia biologica, 2014, Volume: 60, Issue:4

    Topics: Animals; Anxiety; Apoptosis; Behavior, Animal; CA1 Region, Hippocampal; CA3 Region, Hippocampal; Cel

2014
Oxytocin and MDMA ('Ecstasy') enhance social reward in rats.
    Psychopharmacology, 2015, Volume: 232, Issue:14

    Topics: Animals; Anxiety; Arginine Vasopressin; Conditioning, Operant; Dose-Response Relationship, Drug; Mal

2015
Reduced Contextual Discrimination following Alcohol Consumption or MDMA Administration in Mice.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Alcohol Drinking; Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition;

2015
How various drugs affect anxiety-related behavior in male and female rats prenatally exposed to methamphetamine.
    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 2016, Volume: 51

    Topics: Analgesics; Analysis of Variance; Animals; Anxiety; Central Nervous System Stimulants; Estrous Cycle

2016
Mephedrone and 3,4-methylenedioxy-methamphetamine: Comparative psychobiological effects as reported by recreational polydrug users.
    Journal of psychopharmacology (Oxford, England), 2016, Volume: 30, Issue:12

    Topics: Adult; Anger; Anxiety; Cross-Sectional Studies; Female; Humans; Illicit Drugs; Male; Methamphetamine

2016
Ritanserin-sensitive receptors modulate the prosocial and the anxiolytic effect of MDMA derivatives, DOB and PMA, in zebrafish.
    Behavioural brain research, 2016, 11-01, Volume: 314

    Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Hallucinogens; Motor Activity; N-Methyl-3,4

2016
Acute behavioral effects of co-administration of mephedrone and MDMA in mice.
    Pharmacological reports : PR, 2017, Volume: 69, Issue:2

    Topics: Animals; Antidepressive Agents; Anxiety; Cognition; Depression; Disease Models, Animal; Drug Interac

2017
(+/-)-3,4-Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks.
    Neuropharmacology, 2008, Volume: 55, Issue:7

    Topics: Animals; Anxiety; Behavior, Animal; Body Temperature; Body Weight; Hallucinogens; Learning; Male; Ma

2008
Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:2

    Topics: Adolescent; Adult; Anxiety; Depression; Female; Hallucinogens; Humans; Male; Marijuana Abuse; Multiv

2010
Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence.
    Annals of the New York Academy of Sciences, 2008, Volume: 1139

    Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Animals; Anxiety; Behavior, Animal; Body Temperatu

2008
Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats.
    Psychopharmacology, 2009, Volume: 204, Issue:2

    Topics: Aging; Animals; Anxiety; Body Weight; Cues; Female; Hallucinogens; Learning; Lighting; Maze Learning

2009
Intermittent prenatal MDMA exposure alters physiological but not mood related parameters in adult rat offspring.
    Behavioural brain research, 2010, Jan-20, Volume: 206, Issue:2

    Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Behavior, Animal; Blood Glucose; Body Weight; Corpus

2010
Acute SSRI-induced anxiogenic and brain metabolic effects are attenuated 6 months after initial MDMA-induced depletion.
    Behavioural brain research, 2010, Mar-05, Volume: 207, Issue:2

    Topics: Animals; Anxiety; Axons; Brain; Citalopram; Fluoxetine; Male; N-Methyl-3,4-methylenedioxyamphetamine

2010
Depressive and anxiety symptomatology in ecstasy users: the relative contribution of genes, trauma, life stress and drug use.
    Psychopharmacology, 2010, Volume: 209, Issue:1

    Topics: Adolescent; Adult; Affect; Anxiety; Depression; Female; Hallucinogens; Humans; Male; N-Methyl-3,4-me

2010
Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination.
    Psychopharmacology, 2010, Volume: 212, Issue:4

    Topics: Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Body Weight; Brain; Chromatography, High Pr

2010
Modelling the adverse effects associated with ecstasy use.
    Addiction (Abingdon, England), 2011, Volume: 106, Issue:4

    Topics: Affect; Alcohol Drinking; Anxiety; Binomial Distribution; Confusion; Dose-Response Relationship, Dru

2011
The A2a adenosine receptor modulates the reinforcement efficacy and neurotoxicity of MDMA.
    Journal of psychopharmacology (Oxford, England), 2011, Volume: 25, Issue:4

    Topics: Animals; Anxiety; Astrocytes; Behavior, Animal; Body Temperature; Central Nervous System Stimulants;

2011
Differential behavioral outcomes of 3,4-methylenedioxymethamphetamine (MDMA-ecstasy) in anxiety-like responses in mice.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2011, Volume: 44, Issue:5

    Topics: Animals; Anxiety; Behavior, Animal; Corpus Striatum; Corticosterone; Exploratory Behavior; Fear; Hal

2011
Intermittent ethanol exposure increases long-lasting behavioral and neurochemical effects of MDMA in adolescent mice.
    Psychopharmacology, 2011, Volume: 218, Issue:2

    Topics: Age Factors; Animals; Anxiety; Behavior, Animal; Brain; Dopamine; Dose-Response Relationship, Drug;

2011
Behavioural and neuroinflammatory effects of the combination of binge ethanol and MDMA in mice.
    Psychopharmacology, 2012, Volume: 221, Issue:3

    Topics: Animals; Anxiety; Behavior, Animal; Body Temperature; Drug Interactions; Ethanol; Hallucinogens; Inf

2012
Subacute effects of ecstasy on mood: an exploration of associated risk factors.
    Journal of psychopharmacology (Oxford, England), 2013, Volume: 27, Issue:1

    Topics: Adult; Affect; Anxiety; Depression; Female; Follow-Up Studies; Humans; Male; Mental Disorders; N-Met

2013
Prior stress interferes with the anxiolytic effect of exercise in C57BL/6J mice.
    Behavioral neuroscience, 2012, Volume: 126, Issue:6

    Topics: Animals; Anti-Anxiety Agents; Anxiety; Fever; Male; Mice; Mice, Inbred C57BL; Motor Activity; N-Meth

2012
Influence of chronic caffeine on MDMA-induced behavioral and neuroinflammatory response in mice.
    Psychopharmacology, 2013, Volume: 226, Issue:2

    Topics: Animals; Anxiety; Astrocytes; Behavior, Animal; Body Temperature; Caffeine; Central Nervous System S

2013
Increased anxiety-related behavior in male and female adult rats following early and late adolescent exposure to 3,4-methylenedioxymethamphetamine (MDMA).
    Pharmacology, biochemistry, and behavior, 2013, Volume: 103, Issue:4

    Topics: Age Factors; Aging; Animals; Anxiety; Female; Male; Maze Learning; N-Methyl-3,4-methylenedioxyamphet

2013
On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA.
    Psychopharmacology, 2002, Volume: 162, Issue:4

    Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Brain Chemistry; Cerebral Cortex; Maze Lear

2002
Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.
    Human psychopharmacology, 2002, Volume: 17, Issue:6

    Topics: Anxiety; Depression; Humans; Illicit Drugs; Internet; Memory Disorders; N-Methyl-3,4-methylenedioxya

2002
Acute and subchronic effects of MDMA ("ecstasy") on anxiety in male mice tested in the elevated plus-maze.
    Progress in neuro-psychopharmacology & biological psychiatry, 2002, Volume: 26, Issue:6

    Topics: Animals; Anxiety; Avoidance Learning; Behavior, Animal; Dose-Response Relationship, Drug; Drug Toler

2002
Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: association with altered 5-HT transporter and receptor density.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:8

    Topics: Animals; Anxiety; Carrier Proteins; Male; Membrane Glycoproteins; Membrane Transport Proteins; N-Met

2003
Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes.
    Psychopharmacology, 2003, Volume: 168, Issue:4

    Topics: Amygdala; Animals; Anxiety; Biogenic Monoamines; Cognition; Corpus Striatum; Depression; Fever; Hipp

2003
Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2004, Volume: 29, Issue:4

    Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Fluids; Body Temperature; Body Weig

2004
Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health.
    Journal of psychopharmacology (Oxford, England), 2003, Volume: 17, Issue:4

    Topics: Adult; Affect; Aggression; Amphetamine-Related Disorders; Anxiety; Decision Making; Hallucinogens; H

2003
MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat.
    Psychopharmacology, 2004, Volume: 173, Issue:3-4

    Topics: Animals; Anxiety; Behavior, Animal; Body Temperature; Corpus Striatum; Dopamine; Dopamine Agents; Dr

2004
The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test.
    Pharmacology, biochemistry, and behavior, 2004, Volume: 77, Issue:4

    Topics: Animals; Anxiety; Drug Interactions; Hippocampus; Illicit Drugs; Male; Maze Learning; N-Methyl-3,4-m

2004
Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat.
    Behavioural brain research, 2004, Mar-02, Volume: 149, Issue:2

    Topics: Analysis of Variance; Animals; Anxiety; Avoidance Learning; Body Temperature; Dose-Response Relation

2004
Psychedelic drugs: the ups and downs of ecstasy.
    Nature, 2004, May-13, Volume: 429, Issue:6988

    Topics: Agaricales; Animals; Anxiety; Brain; Cactaceae; Controlled Clinical Trials as Topic; Female; Halluci

2004
Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period.
    Pharmacology, biochemistry, and behavior, 2004, Volume: 79, Issue:4

    Topics: Age Factors; Animals; Anxiety; Male; Membrane Glycoproteins; Membrane Transport Proteins; Memory Dis

2004
Characteristics of ecstasy users in Sãio Paulo, Brazil.
    Substance use & misuse, 2005, Volume: 40, Issue:3

    Topics: Adult; Anxiety; Brazil; Catchment Area, Health; Depression; Disruptive, Impulse Control, and Conduct

2005
Event-related potentials (ERPs) in ecstasy (MDMA) users during a visual oddball task.
    Biological psychology, 2005, Volume: 69, Issue:3

    Topics: Adult; Anxiety; Attention; Discrimination, Psychological; Electroencephalography; Evoked Potentials;

2005
Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats.
    Physiology & behavior, 2005, Nov-15, Volume: 86, Issue:4

    Topics: Animals; Anxiety; Behavior, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Female;

2005
Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test.
    Neuropharmacology, 2006, Volume: 50, Issue:7

    Topics: Animals; Anxiety; Behavior, Animal; Brain; Male; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine;

2006
Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats.
    Drug and alcohol dependence, 2007, Jan-12, Volume: 86, Issue:2-3

    Topics: Animals; Anxiety; Behavior, Animal; Brain; Brain Chemistry; Drug Interactions; Methamphetamine; N-Me

2007
Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats.
    Psychopharmacology, 2007, Volume: 189, Issue:4

    Topics: Animals; Anxiety; Behavior, Animal; Body Temperature; Brain; Female; Hallucinogens; Hydroxyindoleace

2007
Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.
    Drug and alcohol dependence, 2007, Mar-16, Volume: 87, Issue:2-3

    Topics: Affect; Anxiety; Behavioral Symptoms; Depression; Female; Humans; Male; N-Methyl-3,4-methylenedioxya

2007
Hug drug or thug drug? Ecstasy use and aggressive behavior.
    Violence and victims, 2007, Volume: 22, Issue:1

    Topics: Adult; Affect; Aggression; Amphetamine-Related Disorders; Anxiety; Attention; Concept Formation; Dep

2007
Pathways to ecstasy use in young adults: anxiety, depression or behavioural deviance?
    Drug and alcohol dependence, 2008, Jan-01, Volume: 92, Issue:1-3

    Topics: Adolescent; Adolescent Behavior; Adult; Analysis of Variance; Anxiety; Child; Child Behavior Disorde

2008
Behavioral and neurochemical consequences of multiple MDMA administrations in the rat: role of individual differences in anxiety-related behavior.
    Behavioural brain research, 2008, May-16, Volume: 189, Issue:1

    Topics: Animals; Anxiety; Behavior, Animal; Dopamine; Drug Administration Schedule; Exploratory Behavior; Ha

2008
Subjective reports on the effects of the MDMA ('ecstasy') experience in humans.
    Progress in neuro-psychopharmacology & biological psychiatry, 1995, Volume: 19, Issue:7

    Topics: Adolescent; Adult; Anxiety; Behavior; Depression; Female; Humans; Male; N-Methyl-3,4-methylenedioxya

1995
The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine.
    Pharmacology, biochemistry, and behavior, 1999, Volume: 62, Issue:3

    Topics: Amphetamine; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Diazepam; Dopamine Uptake Inhi

1999
Effects of 3,4-methylenedioxy-methamphetamine (MDMA) on anxiety in mice tested in the light-dark box.
    Progress in neuro-psychopharmacology & biological psychiatry, 2000, Volume: 24, Issue:3

    Topics: Animals; Anxiety; Disease Models, Animal; Exploratory Behavior; Hallucinogens; Light; Male; Mice; Mo

2000
(+/-)-3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats.
    European journal of pharmacology, 2000, Nov-10, Volume: 408, Issue:1

    Topics: Animals; Anxiety; Cats; Electroshock; Environment; Hallucinogens; Interpersonal Relations; Male; Mot

2000
Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy").
    European journal of pharmacology, 2001, Dec-14, Volume: 433, Issue:1

    Topics: Animals; Anxiety; Body Temperature; Illicit Drugs; Male; Maze Learning; Memory Disorders; Motor Acti

2001
A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field.
    Psychopharmacology, 2002, Volume: 159, Issue:2

    Topics: Animals; Anxiety; Behavior, Animal; Male; Maze Learning; Motor Activity; N-Methyl-3,4-methylenedioxy

2002
Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion.
    European journal of pharmacology, 2002, Jun-20, Volume: 446, Issue:1-3

    Topics: Animals; Anxiety; Body Temperature; Brain; Hallucinogens; Male; Maze Learning; Motor Activity; N-Met

2002